In Vitro Studies for Alternative BE Approaches to Comparative Clinical Endpoint BE Studies
Автор: U.S. Food and Drug Administration
Загружено: 2020-11-23
Просмотров: 1266
Elizabeth Bielski from the Office of Generic Drugs discusses the agency’s current perspectives on comparative clinical endpoint BE studies with Orally Inhaled and Nasal Drug Products (OINDPs), as well as the agency’s efforts to address its challenges through alternative BE approaches. The alternative BE approaches recommended in recently posted product-specific guidances (PSGs) for solution-based Metered Dose Inhalers (MDIs) will be described, along with brief discussions on supporting data, critical study parameters, and the potential for expanding alternative BE approaches to more complex orally inhaled products.
Learn more at https://www.fda.gov/drugs/regulatory-...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2020 Playlist - • 2020 CDER Small Business and Industry Assi...
SBIA LinkedIn - / cder-small-business-and-industry-assistance
SBIA Training Resources - https://www.fda.gov/cderbsbialearn
Twitter - / fda_drug_info
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
